New diabetes drug studied in kidney patients
NCT ID NCT07385547
First seen Feb 04, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This early-stage study tests how a single dose of the diabetes drug GL0034 behaves in people with different levels of kidney function. About 40 adults with type 2 diabetes will be grouped by kidney health, from normal to severe impairment. Researchers will measure drug levels in the blood and check for side effects to guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orlando Clinical Research Center (OCRC)
NOT_YET_RECRUITINGOrlando, Florida, 32809, United States
-
Panax Clinical Research
RECRUITINGMiami Lakes, Florida, 33014, United States
-
Syneos Miami
NOT_YET_RECRUITINGMiami, Florida, 33136, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GL0034 (a long-acting GLP-1 receptor agonist)
What this could lead to
If successful, this study could help doctors decide safe dosing of GL0034 for people with type 2 diabetes who also have kidney problems.
What could go wrong
This is a very early Phase 1 study with only 40 people. It only looks at drug levels and safety after one dose, not long-term effects or effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.